You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-SIRPa antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Evan Syndrome
  • Treatment
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Antiphospholipid Syndrome
  • Thrombocytopenia
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5

Completed
  • Paroxysmal Nocturnal Hemoglobinuria
  • Anti-C5 antibody treatment
  • Paris, France
    AP-HP Hôpital Saint Louis
Apr 24, 2023

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25

Not yet recruiting
  • The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
  • CD25 prophylaxis
  • (no location specified)
Jun 20, 2023

Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • transarterial therapies
  • (no location specified)
Nov 27, 2022

Obstetrical History and Anti-HLA Antibodies Level

Not yet recruiting
  • Blood Donors
  • Anti-HLA Antibody
  • Obstetrical history
  • Anti-HLA Antibody tests
  • Bordeaux, France
    Etablissement Français du Sang Nouvelle Aquitaine
Aug 25, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Atypical Hemolytic Uremic Syndrome Trial (Iptacopan)

Not yet recruiting
  • Atypical Hemolytic Uremic Syndrome
  • (no location specified)
Jun 29, 2023

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
  • Najing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Sep 26, 2022

s and Anti-thyroid Peroxidase Antibody Positivity in Recurrent

Completed
  • Autoimmune Thyroiditis
  • Recurrent Miscarriage
    • Zonguldak, Turkey
      Zonguldak Bulent Ecevit University Faculty of Medicine
    Dec 26, 2022

    Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

    Recruiting
    • Acute Gout
    • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
    • +6 more
    • Wuhan, Hubei, China
    • +2 more
    Oct 17, 2022

    Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • Hangzhou, Zhejiang, China
      Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
    Jan 30, 2023

    Advanced Solid Tumors Trial in Guangzhou (MR001)

    Not yet recruiting
    • Advanced Solid Tumors
    • Guangzhou, Guangdong, China
      Nanfang Hospital, Southern Medical University
    Nov 12, 2023

    Psoriasis Trial in Shanghai, Kunming (Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection, Placebo)

    Active, not recruiting
    • Psoriasis
    • Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
    • Placebo
    • Shanghai, Shanghai, China
    • +2 more
    Nov 7, 2022

    Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

    Not yet recruiting
    • Solid Tumor, Adult
    • +2 more
    • (no location specified)
    Dec 14, 2022

    Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

    Recruiting
    • Melanoma (Skin)
    • +4 more
    • Bloomington, Minnesota
    • +7 more
    Jan 31, 2023

    Dynamics of Anti-factor VIII Antibody Signature During Treatment

    Not yet recruiting
    • Severe Hemophilia A
    • +2 more
    • no interventions
    • (no location specified)
    Apr 4, 2023

    Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular

    Completed
    • AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
    • Wenzhou, Zhejiang, China
      The First Affiliated Hospital of Wenzhou Medical University
    Nov 6, 2023

    Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • HAIC
    • +8 more
    • Quanzhou, Fujian, China
    • +1 more
    Jan 26, 2023